ArticleJournal of medical microbiology2021
Molecular characterization of carbapenem-resistant
Article in Journal of medical microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Global Epidemiology and Antimicrobial Resistance of Klebsiella Pneumoniae Carbapenemase (KPC)-Producing Gram-Negative Clinical Isolates: A Review.Microorganisms · 2025Review
- Dissemination ofMicrobiology spectrum · 2025Article
- Clonal and horizontal transmission of carbapenem-resistant Enterobacterales strains and genes via flies.Gut pathogens · 2024Article
- Ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae accompanied hypermucoviscosity acquisition.BMC microbiology · 2024Article
- Monitoring ofInfection and drug resistance · 2024Article
- Genomic Epidemiology and Characterization of Carbapenem-Resistant Klebsiella pneumoniae in ICU Inpatients in Henan Province, China: a Multicenter Cross-Sectional Study.Microbiology spectrum · 2023Article
- Molecular Characterization and Epidemiology of Carbapenem-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2023Article
- The Efficacy and Influencing Factors of Polymyxin B in High-Level Carbapenem-ResistantInfection and drug resistance · 2023Article
- Emergence of Tigecycline and Carbapenem-ResistantInfection and drug resistance · 2023Article
- Multicenter Genomic Analysis of Carbapenem-Resistant Klebsiella pneumoniae from Bacteremia in China.Microbiology spectrum · 2022Article
- Carbapenem-Resistant Gram-Negative Bacilli Causing Ventilator Associated Pneumonia: Study of MASTDISCS Combi Carba Plus for Detection of Carbapenemase Producing Enterobacterales.Infection and drug resistance · 2022Article
- Prevalence and risk factors of carbapenem-resistantFrontiers in microbiology · 2022Article
- Comparative Genomics Revealed Fluoroquinolone Resistance Determinants and OmpF Deletion in Carbapenem-ResistantFrontiers in microbiology · 2022Article
- Tandem Repeat ofInfection and drug resistance · 2022Article
- Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing KlebsiellaEmerging microbes & infections · 2021Article
- Characteristics of Carbapenem-Resistant Gram-Negative Bacilli in Patients with Ventilator-Associated Pneumonia.Antibiotics (Basel, Switzerland) · 2021Article
- Molecular Analysis and Antimicrobial Resistance Pattern of Tigecycline-Non-SusceptibleInfection and drug resistance · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.